Does the media prefer ANIP or HELP?

In the previous week, Cybin had 3 more articles in the media than ANI Pharmaceuticals. MarketBeat recorded 17 mentions for Cybin and 14 mentions for ANI Pharmaceuticals. Cybin's average media sentiment score of 1.00 beat ANI Pharmaceuticals' score of 0.84 indicating that Cybin is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ANI Pharmaceuticals 7 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cybin 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is PGEN or HELP more profitable?

Cybin has a net margin of 0.00% compared to Precigen's net margin of -646.99%. Precigen's return on equity of 717.50% beat Cybin's return on equity. Company Net Margins Return on Equity Return on Assets Precigen -646.99% 717.50% 58.48% Cybin N/A -68.27% -58.26%

Does the media prefer PGEN or HELP?

In the previous week, Cybin had 14 more articles in the media than Precigen. MarketBeat recorded 17 mentions for Cybin and 3 mentions for Precigen. Precigen's average media sentiment score of 1.30 beat Cybin's score of 1.00 indicating that Precigen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Precigen 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cybin 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is HELP or STOK more profitable?

Cybin has a net margin of 0.00% compared to Stoke Therapeutics' net margin of -529.20%. Stoke Therapeutics' return on equity of -48.84% beat Cybin's return on equity. Company Net Margins Return on Equity Return on Assets Cybin N/A -68.27% -58.26% Stoke Therapeutics -529.20% -48.84% -42.27%

Does the media refer more to HELP or STOK?

In the previous week, Cybin had 9 more articles in the media than Stoke Therapeutics. MarketBeat recorded 17 mentions for Cybin and 8 mentions for Stoke Therapeutics. Cybin's average media sentiment score of 1.00 beat Stoke Therapeutics' score of 0.96 indicating that Cybin is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cybin 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Stoke Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, HELP or AAPG?

Cybin has higher earnings, but lower revenue than Ascentage Pharma Group International. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cybin N/A N/A -$148M -$4.23 N/A Ascentage Pharma Group International $574.12M 3.32 -$177.71M N/A N/A

Is HELP or AAPG more profitable?

Ascentage Pharma Group International's return on equity of 0.00% beat Cybin's return on equity. Company Net Margins Return on Equity Return on Assets Cybin N/A -68.27% -58.26% Ascentage Pharma Group International N/A N/A N/A

Does the media favor HELP or AAPG?

In the previous week, Cybin had 13 more articles in the media than Ascentage Pharma Group International. MarketBeat recorded 17 mentions for Cybin and 4 mentions for Ascentage Pharma Group International. Cybin's average media sentiment score of 1.00 beat Ascentage Pharma Group International's score of 0.99 indicating that Cybin is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cybin 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ascentage Pharma Group International 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is ATAI or HELP more profitable?

Cybin has a net margin of 0.00% compared to Atai Beckley's net margin of -19,019.44%. Cybin's return on equity of -68.27% beat Atai Beckley's return on equity. Company Net Margins Return on Equity Return on Assets Atai Beckley -19,019.44% -89.79% -63.58% Cybin N/A -68.27% -58.26%

Does the media prefer ATAI or HELP?

In the previous week, Atai Beckley had 7 more articles in the media than Cybin. MarketBeat recorded 24 mentions for Atai Beckley and 17 mentions for Cybin. Cybin's average media sentiment score of 1.00 beat Atai Beckley's score of 0.64 indicating that Cybin is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Atai Beckley 9 Very Positive mention(s) 5 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cybin 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Cybin (HELP) Competitors

$7.04 +0.53 (+8.14%)

Closing price 04:00 PM Eastern

Extended Trading

$7.10 +0.05 (+0.78%)

As of 06:42 PM Eastern

Compare

HELP vs. ANIP, PGEN, STOK, AAPG, and ATAI

Should you buy Cybin stock or one of its competitors? MarketBeat compares Cybin with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cybin include ANI Pharmaceuticals (ANIP), Precigen (PGEN), Stoke Therapeutics (STOK), Ascentage Pharma Group International (AAPG), and Atai Beckley (ATAI). These companies are all part of the "pharmaceutical products" industry.

How does Cybin compare to ANI Pharmaceuticals?

ANI Pharmaceuticals (NASDAQ:ANIP) and Cybin (NASDAQ:HELP) are both small-cap pharmaceutical products companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, dividends, risk, earnings, profitability, media sentiment and valuation.

ANI Pharmaceuticals has a net margin of 9.98% compared to Cybin's net margin of 0.00%. ANI Pharmaceuticals' return on equity of 27.51% beat Cybin's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ANI Pharmaceuticals	9.98%	27.51%	10.02%
Cybin	N/A	-68.27%	-58.26%

76.1% of ANI Pharmaceuticals shares are owned by institutional investors. Comparatively, 17.9% of Cybin shares are owned by institutional investors. 8.1% of ANI Pharmaceuticals shares are owned by company insiders. Comparatively, 15.0% of Cybin shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

ANI Pharmaceuticals has higher revenue and earnings than Cybin. Cybin is trading at a lower price-to-earnings ratio than ANI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ANI Pharmaceuticals	$883.37M	2.11	$78.34M	$3.95	20.74
Cybin	N/A	N/A	-$148M	-$4.23	N/A

ANI Pharmaceuticals has a beta of 0.43, indicating that its share price is 57% less volatile than the broader market. Comparatively, Cybin has a beta of 0.62, indicating that its share price is 38% less volatile than the broader market.

ANI Pharmaceuticals presently has a consensus target price of $107.33, indicating a potential upside of 31.02%. Cybin has a consensus target price of $55.00, indicating a potential upside of 681.25%. Given Cybin's stronger consensus rating and higher possible upside, analysts clearly believe Cybin is more favorable than ANI Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ANI Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.75
Cybin	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00

In the previous week, Cybin had 3 more articles in the media than ANI Pharmaceuticals. MarketBeat recorded 17 mentions for Cybin and 14 mentions for ANI Pharmaceuticals. Cybin's average media sentiment score of 1.00 beat ANI Pharmaceuticals' score of 0.84 indicating that Cybin is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ANI Pharmaceuticals	7 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cybin	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

ANI Pharmaceuticals beats Cybin on 9 of the 15 factors compared between the two stocks.

How does Cybin compare to Precigen?

Precigen (NASDAQ:PGEN) and Cybin (NASDAQ:HELP) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, earnings, risk, dividends, analyst recommendations, profitability and media sentiment.

In the previous week, Cybin had 14 more articles in the media than Precigen. MarketBeat recorded 17 mentions for Cybin and 3 mentions for Precigen. Precigen's average media sentiment score of 1.30 beat Cybin's score of 1.00 indicating that Precigen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Precigen	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cybin	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cybin has a net margin of 0.00% compared to Precigen's net margin of -646.99%. Precigen's return on equity of 717.50% beat Cybin's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Precigen	-646.99%	717.50%	58.48%
Cybin	N/A	-68.27%	-58.26%

Cybin has lower revenue, but higher earnings than Precigen. Precigen is trading at a lower price-to-earnings ratio than Cybin, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Precigen	$9.68M	182.31	-$250.64M	-$1.18	N/A
Cybin	N/A	N/A	-$148M	-$4.23	N/A

Precigen presently has a consensus target price of $12.50, suggesting a potential upside of 152.53%. Cybin has a consensus target price of $55.00, suggesting a potential upside of 681.25%. Given Cybin's stronger consensus rating and higher possible upside, analysts plainly believe Cybin is more favorable than Precigen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Precigen	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Cybin	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00

33.5% of Precigen shares are owned by institutional investors. Comparatively, 17.9% of Cybin shares are owned by institutional investors. 41.4% of Precigen shares are owned by insiders. Comparatively, 15.0% of Cybin shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Precigen has a beta of 1, suggesting that its share price has a similar volatility profile to the broader market.Comparatively, Cybin has a beta of 0.62, suggesting that its share price is 38% less volatile than the broader market.

Summary

Precigen beats Cybin on 8 of the 15 factors compared between the two stocks.

How does Cybin compare to Stoke Therapeutics?

Cybin (NASDAQ:HELP) and Stoke Therapeutics (NASDAQ:STOK) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, risk, profitability, analyst recommendations, institutional ownership and media sentiment.

Stoke Therapeutics has higher revenue and earnings than Cybin. Stoke Therapeutics is trading at a lower price-to-earnings ratio than Cybin, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cybin	N/A	N/A	-$148M	-$4.23	N/A
Stoke Therapeutics	$184.42M	9.83	-$6.89M	-$2.81	N/A

Cybin currently has a consensus price target of $55.00, indicating a potential upside of 681.25%. Stoke Therapeutics has a consensus price target of $42.00, indicating a potential upside of 44.28%. Given Cybin's stronger consensus rating and higher possible upside, analysts plainly believe Cybin is more favorable than Stoke Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cybin	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00
Stoke Therapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

In the previous week, Cybin had 9 more articles in the media than Stoke Therapeutics. MarketBeat recorded 17 mentions for Cybin and 8 mentions for Stoke Therapeutics. Cybin's average media sentiment score of 1.00 beat Stoke Therapeutics' score of 0.96 indicating that Cybin is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cybin	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Stoke Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cybin has a beta of 0.62, indicating that its share price is 38% less volatile than the broader market. Comparatively, Stoke Therapeutics has a beta of 1.17, indicating that its share price is 17% more volatile than the broader market.

Cybin has a net margin of 0.00% compared to Stoke Therapeutics' net margin of -529.20%. Stoke Therapeutics' return on equity of -48.84% beat Cybin's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cybin	N/A	-68.27%	-58.26%
Stoke Therapeutics	-529.20%	-48.84%	-42.27%

17.9% of Cybin shares are owned by institutional investors. 15.0% of Cybin shares are owned by company insiders. Comparatively, 9.6% of Stoke Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Cybin beats Stoke Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Cybin compare to Ascentage Pharma Group International?

Cybin (NASDAQ:HELP) and Ascentage Pharma Group International (NASDAQ:AAPG) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, dividends, earnings, valuation, institutional ownership, risk, profitability and analyst recommendations.

Cybin currently has a consensus target price of $55.00, indicating a potential upside of 681.25%. Ascentage Pharma Group International has a consensus target price of $46.43, indicating a potential upside of 127.59%. Given Cybin's higher possible upside, analysts plainly believe Cybin is more favorable than Ascentage Pharma Group International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cybin	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00
Ascentage Pharma Group International	0 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.20

Cybin has a beta of 0.62, meaning that its stock price is 38% less volatile than the broader market. Comparatively, Ascentage Pharma Group International has a beta of 0.09, meaning that its stock price is 91% less volatile than the broader market.

17.9% of Cybin shares are owned by institutional investors. 15.0% of Cybin shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Cybin had 13 more articles in the media than Ascentage Pharma Group International. MarketBeat recorded 17 mentions for Cybin and 4 mentions for Ascentage Pharma Group International. Cybin's average media sentiment score of 1.00 beat Ascentage Pharma Group International's score of 0.99 indicating that Cybin is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cybin	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ascentage Pharma Group International	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ascentage Pharma Group International's return on equity of 0.00% beat Cybin's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cybin	N/A	-68.27%	-58.26%
Ascentage Pharma Group International	N/A	N/A	N/A

Cybin has higher earnings, but lower revenue than Ascentage Pharma Group International.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cybin	N/A	N/A	-$148M	-$4.23	N/A
Ascentage Pharma Group International	$574.12M	3.32	-$177.71M	N/A	N/A

Summary

Cybin beats Ascentage Pharma Group International on 7 of the 13 factors compared between the two stocks.

How does Cybin compare to Atai Beckley?

Atai Beckley (NASDAQ:ATAI) and Cybin (NASDAQ:HELP) are both pharmaceutical products companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, earnings, profitability, dividends, analyst recommendations, institutional ownership and media sentiment.

Atai Beckley has a beta of 1.56, suggesting that its share price is 56% more volatile than the broader market. Comparatively, Cybin has a beta of 0.62, suggesting that its share price is 38% less volatile than the broader market.

In the previous week, Atai Beckley had 7 more articles in the media than Cybin. MarketBeat recorded 24 mentions for Atai Beckley and 17 mentions for Cybin. Cybin's average media sentiment score of 1.00 beat Atai Beckley's score of 0.64 indicating that Cybin is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Atai Beckley	9 Very Positive mention(s)	5 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cybin	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

28.4% of Atai Beckley shares are owned by institutional investors. Comparatively, 17.9% of Cybin shares are owned by institutional investors. 19.8% of Atai Beckley shares are owned by insiders. Comparatively, 15.0% of Cybin shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Cybin has a net margin of 0.00% compared to Atai Beckley's net margin of -19,019.44%. Cybin's return on equity of -68.27% beat Atai Beckley's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atai Beckley	-19,019.44%	-89.79%	-63.58%
Cybin	N/A	-68.27%	-58.26%

Atai Beckley currently has a consensus price target of $14.38, indicating a potential upside of 101.05%. Cybin has a consensus price target of $55.00, indicating a potential upside of 681.25%. Given Cybin's stronger consensus rating and higher probable upside, analysts clearly believe Cybin is more favorable than Atai Beckley.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atai Beckley	1 Sell rating(s)	5 Hold rating(s)	5 Buy rating(s)	3 Strong Buy rating(s)	2.71
Cybin	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00

Cybin has lower revenue, but higher earnings than Atai Beckley. Atai Beckley is trading at a lower price-to-earnings ratio than Cybin, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atai Beckley	$3.49M	754.70	-$660.05M	-$2.23	N/A
Cybin	N/A	N/A	-$148M	-$4.23	N/A

Summary

Atai Beckley and Cybin tied by winning 8 of the 16 factors compared between the two stocks.

Get Cybin News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HELP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HELP vs. The Competition

Export

Metric	Cybin	Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$491.89M	$3.11B	$4.42B	$12.45B
Dividend Yield	N/A	15.21%	38.37%	9.44%
P/E Ratio	-1.66	13.25	23.73	24.25
Price / Sales	N/A	2,683.57	93.46	87.39
Price / Cash	N/A	25.97	165.68	60.03
Price / Book	1.57	8.65	11.84	6.23
Net Income	-$148M	-$34.05M	$121.47M	$331.94M
7 Day Performance	6.18%	-0.60%	-2.16%	-1.92%
1 Month Performance	64.10%	-1.19%	-2.97%	-0.96%
1 Year Performance	N/A	11.32%	10.66%	18.25%

Cybin Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HELP Cybin	2.9404 of 5 stars	$7.04 +8.1%	$55.00 +681.3%	N/A	$491.89M	N/A	N/A	50	Positive News Analyst Revision Gap Up High Trading Volume
ANIP ANI Pharmaceuticals	3.981 of 5 stars	$80.55 -0.7%	$107.33 +33.3%	+26.3%	$1.84B	$883.37M	20.39	600
PGEN Precigen	3.1726 of 5 stars	$5.12 -1.0%	$12.50 +144.1%	+176.8%	$1.84B	$9.68M	N/A	190	Positive News
STOK Stoke Therapeutics	2.3583 of 5 stars	$29.13 -1.1%	$42.00 +44.2%	+154.6%	$1.83B	$184.42M	N/A	100	Analyst Forecast
AAPG Ascentage Pharma Group International	3.8943 of 5 stars	$19.24 -1.8%	$46.43 +141.3%	-45.1%	$1.83B	$82.10M	N/A	600

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:HELP) was last updated on 7/16/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cybin (HELP) Competitors

HELP vs. ANIP, PGEN, STOK, AAPG, and ATAI

How does Cybin compare to ANI Pharmaceuticals?

Summary

How does Cybin compare to Precigen?

Summary

How does Cybin compare to Stoke Therapeutics?

Summary

How does Cybin compare to Ascentage Pharma Group International?

Summary

How does Cybin compare to Atai Beckley?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HELP vs. The Competition

Cybin Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cybin (HELP) Competitors

HELP vs. ANIP, PGEN, STOK, AAPG, and ATAI

How does Cybin compare to ANI Pharmaceuticals?

Is ANIP or HELP more profitable?

Do insiders and institutionals believe in ANIP or HELP?

Which has better earnings & valuation, ANIP or HELP?

Which has more risk and volatility, ANIP or HELP?

Do analysts recommend ANIP or HELP?

Does the media prefer ANIP or HELP?

Summary

How does Cybin compare to Precigen?

Does the media prefer PGEN or HELP?

Is PGEN or HELP more profitable?

Which has higher valuation & earnings, PGEN or HELP?

Do analysts rate PGEN or HELP?

Do institutionals and insiders hold more shares of PGEN or HELP?

Which has more risk and volatility, PGEN or HELP?

Summary

How does Cybin compare to Stoke Therapeutics?

Which has preferable earnings and valuation, HELP or STOK?

Do analysts rate HELP or STOK?

Does the media refer more to HELP or STOK?

Which has more risk and volatility, HELP or STOK?

Is HELP or STOK more profitable?

Do institutionals and insiders believe in HELP or STOK?

Summary

How does Cybin compare to Ascentage Pharma Group International?

Do analysts recommend HELP or AAPG?

Which has more risk and volatility, HELP or AAPG?

Do institutionals and insiders believe in HELP or AAPG?

Does the media favor HELP or AAPG?

Is HELP or AAPG more profitable?

Which has stronger earnings and valuation, HELP or AAPG?

Summary

How does Cybin compare to Atai Beckley?

Which has more risk & volatility, ATAI or HELP?

Does the media prefer ATAI or HELP?

Do institutionals & insiders believe in ATAI or HELP?

Is ATAI or HELP more profitable?

Do analysts recommend ATAI or HELP?

Which has stronger earnings and valuation, ATAI or HELP?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HELP vs. The Competition

Cybin Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools